BASF Plant Science is a subsidiary of BASF in which all plant biotechnology activities are consolidated. The GmbH was founded in 1998 and employs approximately 700 people at 6 different locations worldwide. The headquarters of BASF Plant Science is located in Research Triangle Park (North Carolina, USA). Plant Science has research sites in the US, Canada and Europe. At these locations the company is mainly developing genetically modified seeds.

Danisco US, Inc. manufactures synthetic resins, synthetic rubbers and industrial chemicals. The company is headquartered in Wilmington, DE.

National Research Council of Canada, provides research & development. It services include research programs and collaboration opportunities, technical and advisory services, licensing opportunities and industrial research assistance program. The company was founded by Graham W. Burton and is headquartered in Ottawa, ON.

ARTES Biotechnology GmbH developes biopharmaceutical production processes. Its products include biosimilars, enzymes and proteins and vaccines. The firm offers cell line development, process development, manufacturing and technology transfer. The company was founded in 2002 by Michael Piontek and is headquartered in Langenfeld, Germany.

Provides bio-pharmaceutical research development services

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Pfizer Inc. (NYSE: PFE, /ˈfaɪzər/) is an American multinational pharmaceutical corporation headquartered in New York City was founded in 1849, based in New York City and was listed on New York Stock Exchange. It is one of the world's largest pharmaceutical companies. It is listed on the New York Stock Exchange, and its shares have been a component of the Dow Jones Industrial Average since 2004. Pfizer ranked No. 57 on the 2018 Fortune 500 list of the largest United States corporations by total revenue.

Doheny Eye Institute is an American private company located in Los Angeles, CA. The firm provides eye care related research and education programs. Marissa Goldberg is currently the CEO of the company.\nThe company says this about itself: For more than 70 years, Doheny Eye Institute has been at the forefront of vision science. From seeking new ways to free blockages that prevent fluid drainage in glaucoma, to replacing retinal cells in age-related macular degeneration, to providing colleagues worldwide with standardized analyses of anatomical changes in the eyes of patients, Doheny clinician-scientists and researchers are changing how people see �� and also how they think about the future of vision. Doheny Eye Institute and UCLA Stein Eye Institute have joined forces to offer the best patient care, vision research, and education. This affiliation combines the strength, reputation, and distinction of two of the nation's top eye institutions to advance vision research, education, and patient care in California.

Part of Kitasato University, The Kitasato Institute is a company headquartered in Tokyo, Japan, that operates a research institution.

Hoechst AG produced specialty chemicals and pharmaceutical products. It products ranged in areas of heart cycle, thrombose, central nervous system, onkologie, diabetes, metabolic illnesses, internal medicine and vaccines. Founded in 1863, the company was headquartered in Frankfurt am Main, Germany.

Sirna Therapeutics, Inc. was a San Francisco, California based biotechnology company that explored the use of RNA interference in human disease therapy. Sirna's development pipeline includes several small interfering RNA (siRNA) drugs, thought to stably silence the expression of specific disease-related genes. Sirna's clinical trial of an siRNA-based treatment for age-related macular degeneration is the first such trial for an siRNA drug.

Suzhou Proda Biotechnology Co., Ltd., established on 2012-12-22, Business scope includes biomedicine,Health products,food,cosmetic,medical instruments,Non-hazardous chemical products,Research and development of sewage treatment technology,Technical cooperation,technical consulting,technology transfer;Sales:Non-hazardous chemical products,Class I medical device,cosmetic.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Adheron Therapeutics was established in 2006 as Synovex Corporation. The company’s therapeutic program is based on pioneering work done in the laboratory of Dr. Michael Brenner at Brigham and Women’s Hospital and Harvard Medical School. Dr. Brenner discovered that Cadherin-11 (Cad-11) acts as an “adhesive’ between cells and hanges in these Cad-11 interactions can induce the cells to produce many proteins that influence the cellular environment positively or adversely. Based on this discovery, Adheron is developing a best-in-class antibody tackling a variety of diseases by disrupting the adhesion of cells.

A leader in therapeutic antibodies, ImClone Systems (also called "the company") is committed to advancing oncology care by developing a portfolio of targeted biologic treatments designed to address the medical needs of patients with a variety of cancers. Founded in 1984, ImClone has a rich culture of discovery and deep expertise in oncology. The company has utilized the many advances made in the fields of molecular biology, oncology, genomics, and antibody engineering to build a novel pipeline of product candidates designed to address specific genetic mechanisms involved in cancer growth and development. Beyond its blockbuster marketed product ERBITUX®, ImClone has several additional investigational monoclonal antibodies in various stages of clinical development. Following its acquisition by Eli Lilly and Company in 2008, ImClone Systems is accelerating its antibody pipeline development by leveraging Lilly's global capabilities. ImClone's pipeline has several molecules in mid- to late-stage clinical development targeting virtually all major solid tumor types. Additionally, ImClone plans to advance several additional targets from its research programs into clinical development over the coming years. ImClone's research and clinical development capabilities are augmented by its expertise in the scale-up and manufacturing of biologics. The company's state-of-the-art FDA-approved manufacturing facilities in Branchburg, New Jersey, provide it with one of the largest biologic manufacturing capacities in the world. ImClone's Branchburg campus also houses it clinical development and administration operations. The company's research headquarters are based in New York City and it has international operations in Europe.

Europroteome AG develops diagnostic, immunological, and prognostic tools as well as patient-specific therapies for human epithelial cancers.

Mirrx Therapeutics A/S provides protein production technology. Its technology Blockmirs, is steric antisense blockers that bind to specific microRNA binding sites in target RNAs to thereby prevent microRNA binding to the same site. The company was founded by Hans Thorleif M��ller on July 1, 2009 and is headquartered in Vejle, Denmark.